Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 328-334 , June 2010

The role of the ‘innovative therapies for children with cancer’ (ITCC) European consortium

  • C. Michel Zwaan

      Affiliations

    • Dept. of Ped Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • Corresponding Author InformationCorresponding author. Address: Dept. of Ped Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. Tel.: +31 10 703 6691; fax: +31 10 703 1134.
    • ,
  • Pamela Kearns

      Affiliations

    • Institute for Cancer Studies, School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Huib Caron

      Affiliations

    • Dept. of Ped Oncology/Hematology, Academic Medical Centre/Emma Children’s Hospital, Amsterdam, The Netherlands
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Arnauld Verschuur

      Affiliations

    • Dept. of Ped Oncology/Hematology, Academic Medical Centre/Emma Children’s Hospital, Amsterdam, The Netherlands
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Riccardo Riccardi

      Affiliations

    • Division of Ped Oncology, Università Cattolica di Roma, Policlinico Universitario A. Gemelli, Rome, Italy
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Joachim Boos

      Affiliations

    • Dept. of Ped Haematology and Oncology, University Children’s Hospital Münster, Münster, Germany
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Francois Doz

      Affiliations

    • Dept. of Ped Oncology, Institute Curie, Paris, France
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Birgit Geoerger

      Affiliations

    • Division of Ped Oncology, Università Cattolica di Roma, Policlinico Universitario A. Gemelli, Rome, Italy
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Bruce Morland

      Affiliations

    • Institute for Cancer Studies, School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • Gilles Vassal

      Affiliations

    • Division of Ped Oncology, Università Cattolica di Roma, Policlinico Universitario A. Gemelli, Rome, Italy
    • Dept. of Ped Oncology, Institute Gustave Roussy, Villejuif, France
    • ,
  • On behalf of the ‘innovative therapies for children with cancer’ European consortium

References 

  1. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–256
  2. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children’s oncology group phase 1 study. Blood. 2004;104:2655–2660
  3. Zwaan CM, Den Boer ML, Beverloo HB, et al. Dasatinib (SPRYCEL) in children and adolescents with relapsed or refractory leukemia: preliminary results of the CA180018 phase I/II study. Blood. 2006;108:613a
  4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–2653
  5. Pulsipher MA. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?. Pediatr Blood Cancer. 2004;43:523–533
  6. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1190–1197
  7. Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr. 2008;20:17–22
  8. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children’s oncology group pilot study. J Clin Oncol. 2008;26:3756–3762
  9. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate use basis. Blood. 2003;101:3868–3871
  10. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–970
  11. Rossler J, Geoerger B, Taylor M, Vassal G. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets. 2008;8:76–85
  12. Taussig HB. Thalidomide and phocomelia. Pediatrics. 1962;30:654–659
  13. Chintagumpala M, Blaney SM, Bomgaars LR, et al. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004;22:4394–4400
  14. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a pediatric oncology group study. J Clin Oncol. 1998;16:1723–1728
  15. Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111:2538–2547
  16. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol. 2008;26:399–405
  17. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4:37–45
  18. Taylor JA, Winter L, Geyer LJ, Hawkins DS. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer. 2006;107:1400–1406
  19. Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006;12:5329–5335
  20. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol. 2005;23:8431–8441
  21. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240–250
  22. Vassal G, Michel G, Esperou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113–123
  23. Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia – a randomized phase II clinical trial. Blood. 2008;112:4832–4838
  24. Panetta JC, Iacono LC, Adamson PC, Stewart CF. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res. 2003;9:5068–5077
  25. Panetta JC, Kirstein MN, Gajjar A, et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol. 2003;52:435–441
  26. Georger B, Morland B, Ndiaye A, et al. Target-driven explaoratory study of imatinib mesylate in children with solid malignancies by the innovative therapies for children with cancer (ITCC) European consortium. Eur J Cancer, 2009, April 9, E-pub ahead of print.
  27. Boos J. Off label use – label off use?. Ann Oncol. 2003;14:1–5
  28. Hirschfeld S, Ho PT, Smith M, Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol. 2003;21:1066–1073
  29. Hirschfeld S, Shapiro A, Dagher R, Pazdur R. Pediatric oncology: regulatory initiatives. Oncologist. 2000;5:441–444
  30. Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d’Oncologie Pediatrique (SFOP) and the United Kingdom children cancer study group (UKCCSG). Eur J Cancer. 2008;44:2453–2460
  31. Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French society of pediatric oncology and the United Kingdom children’s cancer study group. J Clin Oncol. 2007;25:356–361
  32. Wagner-Bohn A, Ripkens-Reinhard A, Benninger-Doring G, Boos J. Implementing good clinical practice in two noncommercial phase II studies in children with cancer. Onkologie. 2007;30:21–26
  33. Geoerger B, Gaspar N, Opolon P, et al. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer. 2008;123:209–216
  34. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–940
  35. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008;14:4572–4583
  36. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1198–1206
  37. Holleman A, Cheok MH, Den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533–542
  38. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2008, E-pub ahead of print.
  39. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108:3477–3483
  40. Verschuur A, Zwaan CM. Nederland kan niet achterblijven. Fase-I-onderzoek noodzaak voor kinderen met kanker. Medisch Contact. 2007;62:909–912
  41. Goemans BF, Zwaan C, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19:1536–1542
  42. Stone RM. Targeted agents in AML: much more to do. Best Pract Res Clin Haematol. 2007;20:39–48
  43. Stone RM, De Angelo DJ, Galinsky I, et al. PKC412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004;83(Suppl. 1):89–90

PII: S0305-7372(10)00028-9

doi: 10.1016/j.ctrv.2010.02.008

Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 328-334 , June 2010

Article Tools

* Image Usage & Resolution